Edward Anders Kolb, MD

Getz, K. D., Alonzo, T. A., Sung, L., Meshinchi, S., Gerbing, R. B., Raimondi, S., & Aplenc, R. (2022). Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 69(1). doi:10.1002/pbc.29313

Lamble, A. J., Eidenschink Brodersen, L., Alonzo, T. A., Wang, J., Pardo, L., Sung, L., & Meshinchi, S. (2022). CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 40(3), 252-261. doi:10.1200/JCO.21.01595

Kutny, M. A., Alonzo, T. A., Abla, O., Rajpurkar, M., Gerbing, R. B., Wang, Y.-C., & Gregory, J., Jr. (2022). Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report from the Children's Oncology Group AAML1331 Trial. JAMA Oncology, 8(1), 79-87. doi:10.1001/jamaoncol.2021.5206

Brivio, E., Baruchel, A., Beishuizen, A., Bourquin, J.-P., Brown, P. A., Cooper, T., & Zwaan, C. M. (2022). Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma. European Journal of Cancer, 164, 1-17. doi:10.1016/j.ejca.2021.12.029

Elsayed, A. H., Cao, X., Mitra, A. K., Wu, H., Raimondi, S., Cogle, C., & Lamba, J. K. (2022). Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 40(7), 772-783. doi:10.1200/JCO.21.01422

Pommert, L., Cooper, T. M., Gerbing, R. B., Brodersen, L., Loken, M., Gamis, A., & Kolb, E. A. (2022). Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival. Cancers, 14(3). doi:10.3390/cancers14030616

Barwe, S. P., Sebastian, A., Sidhu, I., Kolb, E. A., & Gopalakrishnapillai, A. (2022). Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of GATA1 and STAG2 Mutations in Induced Pluripotent Stem Cells with Trisomy 21. Cells, 11(4). doi:10.3390/cells11040628

Barwe, S. P., Kisielewski, A., Bonvini, E., Muth, J., Davidson-Moncada, J., Kolb, E. A., & Gopalakrishnapillai, A. (2022). Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia. Journal of Clinical Medicine, 11(5). doi:10.3390/jcm11051333

Heikamp, E. B., Henrich, J. A., Perner, F., Wong, E. M., Hatton, C., Wen, Y., & Armstrong, S. A. (2022). The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. Blood, 139(6), 894-906. doi:10.1182/blood.2021012806

Getz, K. D., Alonzo, T. A., Sung, L., Meshinchi, S., Gerbing, R. B., Raimondi, S., & Aplenc, R. (2022). Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 69(1). doi:10.1002/pbc.29313

Hecht, A., Meyer, J. A., Behnert, A., Wong, E., Chehab, F., Olshen, A., & Stieglitz, E. (2022). Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. Haematologica, 107(1), 178-186. doi:10.3324/haematol.2020.270595

Hecht, A., Meyer, J. A., Behnert, A., Wong, E., Chehab, F., Olshen, A., & Stieglitz, E. (2022). Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. Haematologica, 107(1), 178-186. doi:10.3324/haematol.2020.270595

Kutny, M. A., Alonzo, T. A., Abla, O., Rajpurkar, M., Gerbing, R. B., Wang, Y.-C., & Gregory, J., Jr. (2022). Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report from the Children's Oncology Group AAML1331 Trial. JAMA Oncology, 8(1), 79-87. doi:10.1001/jamaoncol.2021.5206

Dandoy, C. E., Davies, S. M., Ahn, K. W., He, Y., Kolb, A. E., Levine, J., & Eapen, M. (2021). Comparison of total body irradiation versus non-total body irradiation containing regimens for de novo acute myeloid leukemia in children. Haematologica, 106(7), 1839-1845. doi:10.3324/haematol.2020.249458

Kendsersky, N. M., Lindsay, J., Anders Kolb, E., Smith, M. A., Teicher, B. A., Erickson, S. W., & Maris, J. M. (2021). The B7-H3-targeting antibody-Drug conjugate m276-SL-PBD is potently effective against pediatric cancer preclinical solid tumor models. Clinical Cancer Research, 27(10), 2938-2946. doi:10.1158/1078-0432.CCR-20-4221

van Dijk, A. D., Hoff, F. W., Qiu, Y., Gerbing, R. B., Gamis, A. S., Aplenc, R., & Horton, T. M. (2021). Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-KB subunit RelA. Proteomics - Clinical Applications. doi:10.1002/prca.202100072

Kutny, M. A., Alonzo, T. A., Abla, O., Rajpurkar, M., Gerbing, R. B., Wang, Y.-C., & Gregory, J., Jr. (2022). Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report from the Children's Oncology Group AAML1331 Trial. JAMA Oncology, 8(1), 79-87. doi:10.1001/jamaoncol.2021.5206

Smith, S. M., Zhang, S., Sundaram, V., Roth, M., Andolina, J. R., Schapira, L., & Chaudhury, S. (2021). Physician risk perceptions and surveillance practices for tyrosine kinase inhibitor long-term effects in pediatric CML. Pediatric Hematology and Oncology. doi:10.1080/08880018.2021.2017085

Rasche, M., Steidel, E., Zimmermann, M., Bourquin, J.-P., Boztug, H., Janotova, I., & Reinhardt, D. (2021). Second relapse of pediatric patients with acute myeloid leukemia: A report on current treatment strategies and outcome of the AML-BFM study group. Cancers, 13(4), 1-14. doi:10.3390/cancers13040789

Hingorani, P., Roth, M. E., Wang, Y., Zhang, W., Gill, J. B., Harrison, D. J., & Gorlick, R. (2021). ABBV-085, antibody-drug conjugate targeting LRRC15, is effective in osteosarcoma: A report by the pediatric preclinical testing consortium. Molecular Cancer Therapeutics, 20(3), 535-540. doi:10.1158/1535-7163.MCT-20-0406

Rasche, M., Zimmermann, M., Steidel, E., Alonzo, T., Aplenc, R., Bourquin, J.-P., & Reinhardt, D. (2021). Survival following relapse in children with acute myeloid leukemia: A report from aml-bfm and cog. Cancers, 13(10). doi:10.3390/cancers13102336

Kaeding, A. J., Barwe, S. P., Gopalakrishnapillai, A., Ries, R. E., Alonzo, T. A., Gerbing, R. B., & Meshinchi, S. (2021). Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia. Blood Advances, 5(9), 2350-2361. doi:10.1182/BLOODADVANCES.2021004424

O'Brien, M. M., Alonzo, T. A., Cooper, T. M., Levine, J. E., Brown, P. A., Slone, T., & Kolb, E. A. (2021). Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia. Pediatric Blood and Cancer, 68(7). doi:10.1002/pbc.28946

Plana, A., Furner, B., Palese, M., Dussault, N., Birz, S., Graglia, L., & Volchenboum, S. L. (2021). Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer Research. JCO clinical cancer informatics, 5, 1034-1043. doi:10.1200/CCI.21.00075

Sidhu, I., Barwe, S. P., Kiick, K. L., Kolb, E. A., & Gopalakrishnapillai, A. (2021). A 3-D hydrogel based system for hematopoietic differentiation and its use in modeling down syndrome associated transient myeloproliferative disorder. Biomaterials Science, 9(18), 6266-6281. doi:10.1039/d1bm00442e

Tarlock, K., Lamble, A. J., Wang, Y.-C., Gerbing, R. B., Ries, R. E., Loken, M. R., & Meshinchi, S. (2021). CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group. Blood, 138(13), 1137-1147. doi:10.1182/blood.2020009652

Pollard, J. A., Guest, E., Alonzo, T. A., Gerbing, R. B., Loken, M. R., Brodersen, L. E., & Gamis, A. S. (2021). Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 39(28), 3149-3160. doi:10.1200/JCO.20.03048

Elgarten, C. W., Wood, A. C., Li, Y., Alonzo, T. A., Brodersen, L. E., Gerbing, R. B., & Aplenc, R. (2021). Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 68(12). doi:10.1002/pbc.29281

Gopalakrishnapillai, A., Correnti, C. E., Pilat, K., Lin, I., Chan, M. K., Bandaranayake, A. D., & Barwe, S. P. (2021). Immunotherapeutic targeting of mesothelin positive pediatric aml using bispecific t cell engaging antibodies. Cancers, 13(23). doi:10.3390/cancers13235964

Hitzler, J., Alonzo, T., Gerbing, R., Beckman, A., Hirsch, B., Raimondi, S., & Berman, J. N. (2021). High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. Blood, 138(23), 2337-2346. doi:10.1182/blood.2021012206

Huang, B. J., Smith, J. L., Wang, Y.-C., Taghizadeh, K., Leonti, A. R., Ries, R. E., & Meshinchi, S. (2021). CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes. Blood Advances, 5(23), 4963-4968. doi:10.1182/bloodadvances.2021004965

Kutny, M. A., Alonzo, T. A., Abla, O., Rajpurkar, M., Gerbing, R. B., Wang, Y.-C., & Gregory, J., Jr. (2022). Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report from the Children's Oncology Group AAML1331 Trial. JAMA Oncology, 8(1), 79-87. doi:10.1001/jamaoncol.2021.5206

Hecht, A., Meyer, J. A., Behnert, A., Wong, E., Chehab, F., Olshen, A., & Stieglitz, E. (2022). Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. Haematologica, 107(1), 178-186. doi:10.3324/haematol.2020.270595

Nevil, G., Roth, M., Gill, J., Zhang, W., Teicher, B., Erickson, S. W., & Gorlick, R. (2020). Initial in vivo testing of TPO-receptor agonist eltrombopag in osteosarcoma patient-derived xenograft models by the pediatric preclinical testing consortium. Pediatric Hematology and Oncology, 38(1), 8-13. doi:10.1080/08880018.2020.1802539

Kinnaman, Hamill, D., Yabe, M., Powell, J., Benhamida, J., Hasselblatt, M., & Shukla, N. (2020). Aggressive hematopoietic malignancy characterized by biallelic loss of SMARCB1. JCO Precision Oncology, 4, 1280-1284. doi:10.1200/PO.20.00215

Miller, R., Coyne, E., Crowgey, E. L., Eckrich, D., Myers, J. C., Villanueva, R., & Kolb, E. A. (2020). Implementation of a learning healthcare system for sickle cell disease. JAMIA Open, 3(3), 349-359. doi:10.1093/JAMIAOPEN/OOAA024

Kazak, A. E., Chen, F. F., Hwang, W.-T., Askins, M. A., Vega, G., Kolb, E. A., & Barakat, L. P. (2020). Stability and change in family psychosocial risk over 6 months in pediatric cancer and its association with medical and psychosocial healthcare utilization. Pediatric Blood and Cancer, 67(2). doi:10.1002/pbc.28051

Smith, J. L., Ries, R. E., Hylkema, T., Alonzo, T. A., Gerbing, R. B., Santaguida, M. T., & Meshinchi, S. (2020). Comprehensive transcriptome profiling of cryptic CBFA2T3-GLIS2 fusion-positive AML defines novel therapeutic options: A COG and target pediatric AML study. Clinical Cancer Research, 26(3), 726-737. doi:10.1158/1078-0432.CCR-19-1800

Barwe, S. P., Gopalakrisnapillai, A., Mahajan, N., Druley, T. E., Kolb, E. A., & Crowgey, E. L. (2020). Strong concordance between RNA structural and single nucleotide variants identified via next generation sequencing techniques in primary pediatric leukemia and patient-derived xenograft samples. Genomics and Informatics, 18(1). doi:10.5808/GI.2020.18.1.e6

Crowgey, E. L., Mahajan, N., Wong, W. H., Gopalakrishnapillai, A., Barwe, S. P., Kolb, E. A., & Druley, T. E. (2020). Error-corrected sequencing strategies enable comprehensive detection of leukemic mutations relevant for diagnosis and minimal residual disease monitoring. BMC Medical Genomics, 13(1). doi:10.1186/s12920-020-0671-8

Davies, S. M., Iannone, R., Alonzo, T. A., Wang, Y.-C., Gerbing, R., Soni, S., & Leung, W. (2020). A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study. Biology of Blood and Marrow Transplantation, 26(4), 712-717. doi:10.1016/j.bbmt.2019.12.723

Kolb, E. A., Houghton, P. J., Kurmasheva, R. T., Mosse, Y. P., Maris, J. M., Erickson, S. W., & Gorlick, R. (2020). Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report. Pediatric Blood and Cancer, 67(5). doi:10.1002/pbc.28098

Cooper, T. M., Absalon, M. J., Alonzo, T. A., Gerbing, R. B., Leger, K. J., Hirsch, B. A., & Kolb, E. A. (2020). Phase I/II study of CPX-351 followed by fludarabine, cytarabine, and granulocyte-colony stimulating factor for children with relapsed acute myeloid leukemia: A report from the children's oncology group. Journal of Clinical Oncology, 38(19), 2170-2177. doi:10.1200/JCO.19.03306

Harrison, D. J., Gill, J. D., Roth, M. E., Zhang, W., Teicher, B., Erickson, S., & Gorlick, R. (2020). Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium. Pediatric Blood and Cancer, 67(6). doi:10.1002/pbc.28222

Aplenc, R., Meshinchi, S., Sung, L., Alonzo, T., Choi, J., Fisher, B., & Gamis, A. (2020). Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group. Haematologica, 105(7), 1879-1886. doi:10.3324/haematol.2019.220962

Getz, K. D., Sung, L., Alonzo, T. A., Leger, K. J., Gerbing, R. B., Pollard, J. A., & Aplenc, R. (2020). Effect of dexrazoxane on left ventricular systolic function and treatment outcomes in patients with acute myeloid leukemia: A report from the Children's oncology group. Journal of Clinical Oncology, 38(21), 2398-2406. doi:10.1200/JCO.19.02856

Pearson, A. D. J., Zwaan, C. M., Kolb, E. A., Karres, D., Guillot, J., Kim, S. Y., & Vassal, G. (2020). Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. European Journal of Cancer, 136, 116-129. doi:10.1016/j.ejca.2020.04.038

Quagliano, A., Gopalakrishnapillai, A., Anders Kolb, E., & Barwe, S. P. (2020). CD81 knockout promotes chemosensitivity and disrupts in vivo homing and engraftment in acute lymphoblastic leukemia. Blood Advances, 4(18), 4393-4405. doi:10.1182/BLOODADVANCES.2020001592

Gill, J., Zhang, W., Zhang, Z., Roth, M., Harrison, D. J., Rowshan, S., & Gorlick, R. (2020). Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium. Pediatric Blood and Cancer, 67(10). doi:10.1002/pbc.28606

Brodersen, L. E., Gerbing, R. B., Pardo, M. L., Alonzo, T. A., Paine, D., Fritschle, W., & Loken, M. R. (2020). Morphologic remission status is limited compared to DN flow cytometry: a Children's Oncology Group AAML0531 report. Blood Advances, 4(20), 5050-5061. doi:10.1182/BLOODADVANCES.2020002070

Barwe, S. P., Sidhu, I., Kolb, E. A., & Gopalakrishnapillai, A. (2020). Modeling Transient Abnormal Myelopoiesis Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology. Molecular Therapy - Methods and Clinical Development, 19, 201-209. doi:10.1016/j.omtm.2020.09.007

Hecht, A., Meyer, J. A., Behnert, A., Wong, E., Chehab, F., Olshen, A., & Stieglitz, E. (2022). Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. Haematologica, 107(1), 178-186. doi:10.3324/haematol.2020.270595

Currier, A. W., Kolb, E. A., Gorlick, R. G., Roth, M. E., Gopalakrishnan, V., & Sampson, V. B. (2019). p27/Kip1 functions as a tumor suppressor and oncoprotein in osteosarcoma. Scientific Reports, 9(1). doi:10.1038/s41598-019-42450-0

Rokita, J. L., Rathi, K. S., Cardenas, M. F., Upton, K. A., Jayaseelan, J., Cross, K. L., & Maris, J. M. (2019). Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Reports, 29(6), 1675-1689.e9. doi:10.1016/j.celrep.2019.09.071

Athale, U., Hijiya, N., Patterson, B. C., Bergsagel, J., Andolina, J. R., Bittencourt, H., & Johnston, D. L. (2019). Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group. Pediatric Blood and Cancer, 66(9). doi:10.1002/pbc.27827

Murphy, B. R., Roth, M., Kolb, E. A., Alonzo, T., Gerbing, R., & Wells, R. J. (2019). Development of acute lymphoblastic leukemia following treatment for acute myeloid leukemia in children with Down syndrome: A case report and retrospective review of Children's Oncology Group acute myeloid leukemia trials. Pediatric Blood and Cancer, 66(8). doi:10.1002/pbc.27700

McNeer, N. A., Philip, J., Geiger, H., Ries, R. E., Lavallee, V.-P., Walsh, M., & Kentsis, A. (2019). Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. Leukemia, 33(8), 1934-1943. doi:10.1038/s41375-019-0402-3

Crowgey, E. L., Washburn, M. C., Kolb, E. A., & Puffenberger, E. G. (2019). Development of a Novel Next-Generation Sequencing Assay for Carrier Screening in Old Order Amish and Mennonite Populations of Pennsylvania. Journal of Molecular Diagnostics, 21(4), 687-694. doi:10.1016/j.jmoldx.2019.03.004

Pai, A. L. H., Swain, A. M., Chen, F. F., Hwang, W.-T., Vega, G., Carlson, O., & Kazak, A. E. (2019). Screening for Family Psychosocial Risk in Pediatric Hematopoietic Stem Cell Transplantation with the Psychosocial Assessment Tool. Biology of Blood and Marrow Transplantation, 25(7), 1374-1381. doi:10.1016/j.bbmt.2019.03.012

Lowery, C. D., Dowless, M., Renschler, M., Blosser, W., VanWye, A. B., Stephens, J. R., & Stancato, L. F. (2019). Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models. Clinical Cancer Research, 25(7), 2278-2289. doi:10.1158/1078-0432.CCR-18-2728

Dupuis, L. L., Tamura, R. N., Kelly, K. M., Krischer, J. P., Langevin, A.-M., Chen, L., & McLean, T. W. (2019). Risk factors for chemotherapy-induced nausea in pediatric patients receiving highly emetogenic chemotherapy. Pediatric Blood and Cancer, 66(4). doi:10.1002/pbc.27584

Bolouri, H., Farrar, J. E., Triche, T., Jr, Ries, R. E., Lim, E. L., Alonzo, T. A., & Meshinchi, S. (2019). Publisher Correction: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions (Nature Medicine, (2017), 24, 1, (103-112), 10.1038/nm.4439). Nature Medicine, 25(3), 530. doi:10.1038/s41591-019-0369-7

Davidow, K. A., Walter, A. W., & Kolb, E. A. (2019). Bone marrow transplant and pediatric multiple myeloma. Pediatric Blood and Cancer, 66(2). doi:10.1002/pbc.27528

Isakoff, M. S., Goldsby, R., Villaluna, D., Krailo, Hingorani, P., Collier, A., & Janeway, K. A. (2019). A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 66(2). doi:10.1002/pbc.27524

Esbenshade, A. J., Kahalley, L. S., Baertschiger, R., Dasgupta, R., Goldsmith, K. C., Nathan, P. C., & Dhall, G. (2019). Mentors' perspectives on the successes and challenges of mentoring in the COG Young Investigator mentorship program: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 66(10). doi:10.1002/pbc.27920

Kazak, A. E., Swain, A. M., Canter, K., Vega, G., Joffe, N., Deatrick, J. A., & Pai, A. L. H. (2019). A psychosocial clinical care pathway for pediatric hematopoietic stem cell transplantation. Pediatric Blood and Cancer, 66(10). doi:10.1002/pbc.27889

Tarlock, K., Zhong, S., He, Y., Ries, R., Severson, E., Bailey, M., & He, J. (2018). Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling. Oncotarget, 9(41), 26417-26430. doi:10.18632/oncotarget.25443

Dupuis, L. L., Kelly, K. M., Krischer, J. P., Langevin, A.-M., Tamura, R. N., Xu, P., & McLean, T. W. (2018). Acupressure bands do not improve chemotherapy-induced nausea control in pediatric patients receiving highly emetogenic chemotherapy: A single-blinded, randomized controlled trial. Cancer, 124(6), 1188-1196. doi:10.1002/cncr.31198

Scialla, M. A., Canter, K. S., Chen, F. F., Kolb, E. A., Sandler, E., Wiener, L., & Kazak, A. E. (2018). Delivery of care consistent with the psychosocial standards in pediatric cancer: Current practices in the United States. Pediatric Blood and Cancer, 65(3). doi:10.1002/pbc.26869

Mills, C. C., Kolb, E. A., & Sampson, V. B. (2018). Development of chemotherapy with cell-cycle inhibitors for adult and pediatric cancer therapy. Cancer Research, 78(2), 320-325. doi:10.1158/0008-5472.CAN-17-2782

Bolouri, H., Farrar, J. E., Triche, T., Ries, R. E., Lim, E. L., Alonzo, T. A., & Meshinchi, S. (2018). The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nature Medicine, 24(1), 103-112. doi:10.1038/nm.4439

Mills, C. C., Kolb, E. A., & Sampson, V. B. (2017). Recent advances of cell-cycle inhibitor therapies for pediatric cancer. Cancer Research, 77(23), 6489-6498. doi:10.1158/0008-5472.CAN-17-2066

Scialla, M. A., Canter, K. S., Chen, F. F., Kolb, E. A., Sandler, E., Wiener, L., & Kazak, A. E. (2017). Implementing the psychosocial standards in pediatric cancer: Current staffing and services available. Pediatric Blood and Cancer, 64(11). doi:10.1002/pbc.26634

Alexander, T. B., Bhakta, N., Kolb, E. A., & Rubnitz, J. E. (2017). Opportunities for expanding clinical trial enrollment for relapsed and refractory pediatric acute myeloid leukemia in the United States and Canada. Pediatric Blood and Cancer, 64(11). doi:10.1002/pbc.26632

Tarlock, K., Alonzo, T. A., Loken, M. R., Gerbing, R. B., Ries, R. E., Aplenc, R., & Meshinchi, S. (2017). Disease characteristics and prognostic implications of cell-surface FLT3 receptor (CD135) expression in pediatric acute myeloid leukemia: A report from the Children's Oncology Group. Clinical Cancer Research, 23(14), 3649-3656. doi:10.1158/1078-0432.CCR-16-2353

Vetter, N. S., Kolb, E. A., Mills, C. C., & Sampson, V. B. (2017). The microtubule network and cell death are regulated by an miR-34a/stathmin 1/BIIITubulin axis. Molecular Cancer Research, 15(7), 953-964. doi:10.1158/1541-7786.MCR-16-0372

Gopalakrishnapillai, A., Kolb, E. A., McCahan, S. M., & Barwe, S. P. (2017). Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia. Leukemia Research, 58, 91-97. doi:10.1016/j.leukres.2017.05.004

Tomizawa, D., & Kolb, E. A. (2017). Down syndrome and AML: Where do we go from here? Blood, 129(25), 3274-3275. doi:10.1182/blood-2017-04-780031

Bloh, K. M., Bialk, P. A., Gopalakrishnapillai, A., Kolb, E. A., & Kmiec, E. B. (2017). CRISPR/Cas9-Directed Reassignment of the GATA1 Initiation Codon in K562 Cells to Recapitulate AML in Down Syndrome. Molecular Therapy - Nucleic Acids, 7, 288-298. doi:10.1016/j.omtn.2017.04.009

Cartledge, D. M., Robbins, K. M., Drake, K. M., Sternberg, R., Stabley, D. L., Gripp, K. W., & Napper, A. D. (2017). Cytotoxicity of zardaverine in embryonal rhabdomyosarcoma from a Costello syndrome patient. Frontiers in Oncology, 7(APR). doi:10.3389/fonc.2017.00042

Kurmasheva, R. T., Gorlick, R., Kolb, E. A., Keir, S. T., Maris, J. M., Lock, R. B., & Smith, M. A. (2017). Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 64(4). doi:10.1002/pbc.26304

Lock, R., Carol, H., Maris, J. M., Kolb, E. A., Gorlick, R., Reynolds, C. P., & Smith, M. A. (2017). Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 64(4). doi:10.1002/pbc.26263

Murphy, B., Yin, H., Maris, J. M., Kolb, E. A., Gorlick, R., Reynolds, C. P., & Houghton, P. J. (2016). Evaluation of alternative in vivo drug screening methodology: A single mouse analysis. Cancer Research, 76(19), 5798-5809. doi:10.1158/0008-5472.CAN-16-0122

Kang, M. H., Reynolds, C. P., Kolb, E. A., Gorlick, R., Carol, H., Lock, R., & Smith, M. A. (2016). Initial Testing (Stage 1) of MK-8242: A Novel MDM2 Inhibitor: by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 63(10), 1744-1752. doi:10.1002/pbc.26064

Gopalakrishnapillai, A., Kolb, E. A., Dhanan, P., Bojja, A. S., Mason, R. W., Corao, D., & Barwe, S. P. (2016). Generation of pediatric leukemia xenograft models in NSG-B2m mice: Comparison with NOD/SCID mice. Frontiers in Oncology, 6(JUN). doi:10.3389/fonc.2016.00162

Maxson, J. E., Ries, R. E., Wang, Y.-C., Gerbing, R. B., Kolb, E. A., Thompson, S. L., & Meshinchi, S. (2016). CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML. Blood, 127(24), 3094-3098. doi:10.1182/blood-2016-04-709899

Attiyeh, E. F., Maris, J. M., Lock, R., Reynolds, C. P., Kang, M. H., Carol, H., & Smith, M. A. (2016). Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. Pediatric Blood and Cancer, 63(2), 276-286. doi:10.1002/pbc.25727

Sampson, V. B., Vetter, N. S., Zhang, W., Patil, P. U., Mason, R. W., George, E., & Kolb, E. A. (2016). Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma. Oncotarget, 7(52), 86594-86607. doi:10.18632/oncotarget.13358

Roth, M., Barris, D. M., Piperdi, S., Kuo, V., Everts, S., Geller, D., & Gorlick, R. (2016). Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma. Pediatric Blood and Cancer, 63(1), 32-38. doi:10.1002/pbc.25688

Caywood, E. H., & Kolb, E. A. (2015). Challenges in converting Acute Myeloid Leukemia (AML) genomics into AML clinical trials. Journal of Clinical Oncology, 33(36), 4238-4239. doi:10.1200/JCO.2015.63.9252

Kolb, E. A., & Meshinchi, S. (2015). Acute myeloid leukemia in children and adolescents: Identification of new molecular targets brings promise of new therapies. Hematology (United States), 2015(1), 507-513. doi:10.1182/asheducation-2015.1.507

Reynolds, C. P., Kang, M. H., Maris, J. M., Kolb, E. A., Gorlick, R., Wu, J., & Smith, M. A. (2015). Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 62(11), 1897-1905. doi:10.1002/pbc.25611

Gopalakrishnapillai, A., Kolb, E. A., Dhanan, P., Mason, R. W., Napper, A., & Barwe, S. P. (2015). Disruption of Annexin II /p11 interaction suppresses leukemia cell binding, homing and engraftment, and sensitizes the leukemia cells to chemotherapy. PLoS ONE, 10(10). doi:10.1371/journal.pone.0140564

Zwaan, C. M., Kolb, E. A., Reinhardt, D., Abrahamsson, J., Adachi, S., Aplenc, R., & Kaspers, G. J. L. (2015). Collaborative efforts driving progress in pediatric acute myeloid leukemia. Journal of Clinical Oncology, 33(27), 2949-2962. doi:10.1200/JCO.2015.62.8289

Sampson, V. B., Yoo, S., Kumar, A., Vetter, N. S., & Kolb, E. A. (2015). MicroRNAs and Potential Targets in Osteosarcoma: Review. Frontiers in Pediatrics, 3. doi:10.3389/fped.2015.00069

Houghton, P. J., Kurmasheva, R. T., Kolb, E. A., Gorlick, R., Maris, J. M., Wu, J., & Smith, M. A. (2015). Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(R)) by the Pediatric Preclinical Testing Program (PPTP). Pediatric Blood and Cancer, 62(7), 1214-1221. doi:10.1002/pbc.25474

Kolb, E. A., Gorlick, R., Keir, S. T., Maris, J. M., Kang, M. H., Reynolds, C. P., & Smith, M. A. (2015). Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 62(6), 1106-1109. doi:10.1002/pbc.25329

Kolb, E. A., Sampson, V., Stabley, D., Walter, A., Sol-Church, K., Cripe, T., & Blaney, S. M. (2015). A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: A Children's Oncology Group Phase I Consortium report. Pediatric Blood and Cancer, 62(5), 751-758. doi:10.1002/pbc.25464

Smith, M. A., Reynolds, C. P., Kang, M. H., Kolb, E. A., Gorlick, R., Carol, H., & Houghton, P. J. (2015). Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric Cancer Models in the Pediatric Preclinical Testing Program. Clinical Cancer Research, 21(4), 819-832. doi:10.1158/1078-0432.CCR-14-2572

Smith, M. A., Hampton, O. A., Reynolds, C. P., Kang, M. H., Maris, J. M., Gorlick, R., & Houghton, P. J. (2015). Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatric Blood and Cancer, 62(1), 91-98. doi:10.1002/pbc.25201